Cell Therapy

News

Abeona prices rare cell disorder gene therapy at $3.1m

Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).

News

Alcon claims control of cell therapy firm Aurion

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive.

Oncology

Patient-focused manufacturing models for personalised therap...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.

R&D

Paul Hasting and Jonah Comstock interview at JP Morgan 2025

JP Morgan Week 2025 – Paul Hastings

At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta, to talk about NK cells and autoimmune diseases.

Oncology

Access to cells for CGT is closer than you think

So far, advanced therapy developers have been focusing on partnerships with specific hospitals for collecting patient cellular materials, and there are long-term concerns over the ability f

R&D

Partner Content

4th Cell Therapy Potency Assay Summit

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical.